Cerity Partners
ANIK icon

Cerity Partners’s Anika Therapeutics ANIK Stock Holding History

Cerity Partners’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$595K Buy
40,662
+5,196
+15% +$77K ﹤0.01% 2326
2026
Q1 		$514K Buy
35,466
+3,691
+12% +$42.8K ﹤0.01% 2269
2025
Q4 		$305K Buy
31,775
+1,575
+5% +$15.1K ﹤0.01% 2405
2025
Q3 		$284K Buy
30,200
+333
+1% +$3.18K ﹤0.01% 2315
2025
Q2 		$316K Buy
29,867
+425
+1% +$5.36K ﹤0.01% 2131
2025
Q1 		$443K Buy
+29,442
New +$490K ﹤0.01% 1840
2023
Q2 		– Sell
-332
Closed -$364K – 1650
2023
Q1 		$364K Buy
+332
New +$9.88K ﹤0.01% 1442

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cerity Partners's ANIK Position: Q2 2026 in Review

Cerity Partners increased its Anika Therapeutics (ANIK) stake by 15% in Q2 2026, buying an estimated $77K and bringing the position to 40,662 shares worth $595K. The position accounts for ﹤0.01% of the portfolio, ranked #2326.

Cerity Partners first reported a position in ANIK in Q1 2023 and has held it in 7 quarters since. 123 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Cerity Partners held 40,662 shares of Anika Therapeutics worth $595K as of Q2 2026.
  • Cerity Partners bought 5,196 Anika Therapeutics shares in Q2 2026, an estimated $77K.
  • Anika Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2326 holding.
  • Cerity Partners first reported a position in Anika Therapeutics in Q1 2023 and has held it in 7 quarters since.
  • 123 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.